Twenty-Four Weeks of Neoadjuvant Exemestane for Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (SBCCSG 23)

Twenty-Four Weeks of Neoadjuvant Exemestane for Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (SBCCSG 23) - Twenty-Four Weeks of Neoadjuvant Exemestane for Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (SBCCSG 23)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035291

Enrollment

Registered

2018-12-19

Start date

2011-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

24 weeks of neoadjuvant exemestane 25mg/day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: postmenopausal ER positive and HER2 nagative, cStage 2A,2B,3A breast cancer patients

Exclusion criteria

Exclusion criteria: patients already treated for breast cancer patients with a past history of breast cancer or with double cancer patients who should be treated by any other therapy

Design outcomes

Primary

Measure	Time frame
To investigate the changes of primary indication for adjuvant chemotherapy in patients who underwent neoadjuvant exemestane	—

Secondary

Measure	Time frame
1.objective responce rate 2.tumor size 3.method of surgery 4.rate of positive surgical margin 5.PEPI score 6.pathological response 7.PgR 8.DFS 9.OS 10.safety	—

Countries

Japan

Contacts

Public ContactJun Ninomiya

Saitama Breast Cancer Clinical Study Group(SBCCSG) executive office(Ninomiya Hospital)

jninomiya@grape.plala.or.jp048-941-2223

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026